Defense Health Agency Contracting Activity - DHACA
· Federal agency
DoD Gulf War Illness Clinical Trial Award with Multiple-PI Option
The FY13 GWIRP is offering two award mechanisms to evaluate potential interventions for Gulf War Illness: the Clinical Trial Award (CTA) and the Innovative Treatment Evaluation Award (ITEA). The Clinical Trial Award, des...
96
match
Award$0Deadline4590 days agoLocationAlabamaTypegrantLevelFederalClosedposted Jul 11, 2013
✦ AI Summary
Who can apply: Federal-level applicants (see eligibility for details).
Funding amount: total funding pool ~$9,600,000.
Next deadline: November 25, 2013.
Issued by: Defense Health Agency Contracting Activity - DHACA.
The “key facts” mode pulls structured fields directly from the official source posting (amount, deadline, eligibility tags). The AI mode adds a short plain-English narrative on top, generated from the same source. Always verify with the agency before applying.
AI-generated. Always verify with the official source.
Award amount
$0
Deadline
4590 days ago
Nov 25, 2013
Total pool
$9.6M
About this opportunity
The FY13 GWIRP is offering two award mechanisms to evaluate potential interventions for Gulf War Illness: the Clinical Trial Award (CTA) and the Innovative Treatment Evaluation Award (ITEA). The Clinical Trial Award, described in this Program Announcement/Funding Opportunity, is intended to support larger, more definitive (Phase II-III, FDA device class I-III) clinical trials. In contrast, the ITEA supports the initial evaluation of a treatment or intervention in smaller, early phase or pilot clinical trials (Phase II or I/II), and does not require preliminary data. (For information about the ITEA, see http://cdmrp.army.mil/funding/ The CTA mechanism was first offered in FY08. Since then, nine Clinical Trial Award applications have been received, and three have been recommended for funding. The CTA supports execution of clinical trials with the potential to have a significant impact on the health and lives of veterans with GWI. Health outcomes of interest should include effects of interventions on: • Global health measures (biomarkers) and/or functional status • Improvements in symptom complexes ( cognitive function, musculoskeletal/pain symptoms, gastrointestinal problems, skin abnormalities, sleep difficulties), individually and as they may interact with each other • GWI subgroups characterized by symptom or other clinical characteristics New for FY13: The CTA can be used for comparative research of GWI treatments and multi-center trials comparing treatments. Such studies can be executed by a team of investigators led by an Initiating Principal Investigator (PI) with up to three Partnering PIs. Multiple PI Option: The FY13 GWIRP supports collaborative projects to bring a new perspective to GWI research and/or facilitate advancement of GWI treatments through synergistic collaborations. Therefore, the FY13 GWIRP is offering a Multiple PI Option for this award mechanism. The Multiple PI Option is structured so that up to four investigators, each of whom will be designated as a PI and receive a separate award, will work synergistically on a single project. One member of the team will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with the application. The other member(s) will be referred to as the Partnering PI(s) (maximum of three). All the investigators must collaborate to submit a single project examining one or more innovative treatment modalities or comparing untested or novel treatments for GWI symptoms. It should be clear that all investigators have an equal level of intellectual input and effort. Partnering PIs may bring expertise from a field that is applicable to GWI, though the Initiating PI should have demonstrated expertise in GWI research. Multidisciplinary and multi-organizational projects are encouraged. If the project is multi-organizational, PIs should include plans for communication between investigators at each organization. Additionally, participating organizations must be willing to resolve potential intellectual and material property issues and to remove any barriers that might interfere with achieving high levels of cooperation to ensure successful completion of the project. Application responsibilities unique to Partnering PIs will be identified in the supporting sections of this Program Announcement. Applications proposing studies whose principal focus is on the treatment of psychiatric conditions, including post-traumatic stress disorder (PTSD), will be administratively withdrawn and will not be funded under this Program Announcement/Funding Opportunity. While Gulf War veterans are affected by Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease) at twice the rate of veterans who did not serve in the Gulf War, the GWIRP will not accept applications focusing on ALS research.
Read the agency's eligibility checklist before you start — it's almost always shorter than the full NOFO and will tell you in 90 seconds whether to keep going.
Need help getting in touch with the right agency contact?
Create a free account and our specialists will guide you through the application end-to-end.